In August all three Directors bought shares.
Total Market Capitalisation only about £1Million
Yesterdays announcement means there could be a review of the company’s value.
Contents of the link are copied below.
For immediate release 15 September 2011
THERAKIND PRODUCT UPDATE
EU grants approval for Buccolam®
IPSO Ventures plc (“IPSO”), the creator of commercial value from technology, is pleased to report that further to the announcement on 1st July 2011 regarding Therakind, IPSO’s portfolio company, and Buccolam® the European Commission has now granted approval for Buccolam® for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents from 3 months to less than 18 years.
This approval has triggered a further milestone payment for Therakind. Therakind is expected to also receive royalties on sales of this product as Viropharma is now able to actively market this product across Europe.
IPSO has a 36% shareholding in Therakind.
Further information, please contact:
|IPSO Ventures plcNick Rodgers, Chief Executive Officer||Tel: 020 7921 email@example.com|
|Allenby Capital Limited(Nominated adviser and broker)Nick NaylorNick Athanas||Tel: 020 3328 5656|
IPSO Ventures plc is a business creator and active investor in new technologies, principally in the renewable energy and healthcare sector. Its experienced management team focuses on adding commercial value to enable young companies to move forward rapidly.
Please see the financial disclaimer elsewhere on my blog, and take advice from professional advisers before investing in shares.
Update, it is worth noting that Ipso has several other subsidiary companies, or close allies mentioned on their website, Axilica, Medermica, Polyfect Solutions, IPSoL Energy and WildKnowledge. Here’s the link.